Olezarsen (IONIS-APOCIII-LRx)
Familial Chylomicronemia Syndrome (FCS)
ApprovedLaunched as TRYNGOLZA®
Key Facts
Indication
Familial Chylomicronemia Syndrome (FCS)
Phase
Approved
Status
Launched as TRYNGOLZA®
Company
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is a commercial-stage biotech leader with a mission to discover and deliver life-changing RNA-targeted medicines. The company has achieved multiple industry firsts, including the first approved antisense drug, and has successfully transitioned from a research-focused entity to a fully integrated organization with its own commercial capabilities. Its strategy centers on independently launching medicines in neurology and cardiology while selectively partnering in other areas, backed by a deep, late-stage pipeline and a sustainable technology platform.
View full company profile